Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/148928
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Melichar, Bohuslav | - |
dc.contributor.author | Casado, Esther | - |
dc.contributor.author | Bridgewater, John | - |
dc.contributor.author | Bennouna, Jaafar | - |
dc.contributor.author | Campone, Mario | - |
dc.contributor.author | Vitek, Pavel | - |
dc.contributor.author | Delord, Jean-Pierre | - |
dc.contributor.author | Cerman, Jaroslav | - |
dc.contributor.author | Salazar Soler, Ramón | - |
dc.contributor.author | Dvorak, Josef | - |
dc.contributor.author | Sguotti, Chiara | - |
dc.contributor.author | Urban, Patrick | - |
dc.contributor.author | Viraswami-Appanna, Kalyanee | - |
dc.contributor.author | Tan, Eugene | - |
dc.contributor.author | Tabernero Caturla, Josep | - |
dc.date.accessioned | 2020-01-29T15:29:50Z | - |
dc.date.available | 2020-01-29T15:29:50Z | - |
dc.date.issued | 2011-11-22 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | http://hdl.handle.net/2445/148928 | - |
dc.description.abstract | Background: new agents that are active in patients with metastatic colorectal cancer are needed. Patupilone (EPO906; epothilone B) is a novel microtubule-stabilising agent. Methods: patients with advanced colon cancer who progressed after prior treatment regimens received intravenous patupilone (6.5-10.0 mg m(-2)) once every 3 weeks by a 20-min infusion (20MI), 24-h continuous infusion (CI-1D) or 5-day intermittent 16-h infusion (16HI-5D). Adverse events (AEs), dose-limiting toxicities (DLTs), pharmacokinetics and anti-tumour activity were assessed. Results: sixty patients were enrolled. The maximum tolerated dose (MTD) was not reached in the 20MI arm (n=31), as no DLTs were observed. Three patients in the CI-1D arm (n=26) experienced 1 DLT each at 7.5, 8.0 and 9.0 mg m(-2), but MTD was not reached. However, the prolonged 16HI-5D arm was terminated at 6.5 mg m(-2) after two of the three patients developed a DLT. Diarrhoea was the most common AE and DLT, with increased severity at the higher doses (9.0 and 10.0 mg m(-2)). Grade 3 or 4 diarrhoea was observed in 11 (35%) of the patients in the 20MI arm, 4 (15%) of the patients in the CI-1D arm and 2 (67%) of the patients in the 16HI-5D arm. Patupilone activity was observed in the 20MI arm with a disease control rate of 58%, including four confirmed partial responses. The disease control rate in CI-1D arm was 39%. Conclusion: patupilone given once every 3 weeks as a 20-min infusion had promising anti-tumour activity and manageable safety profile at doses that demonstrated therapeutic efficacy. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Cancer Research UK | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1038/bjc.2011.438 | - |
dc.relation.ispartof | British Journal of Cancer, 2011, vol. 105, num. 11, p. 1646-1653 | - |
dc.relation.uri | https://doi.org/10.1038/bjc.2011.438 | - |
dc.rights | (c) Melichar, Bohuslav et al., 2011 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Medicaments antineoplàstics | - |
dc.subject.classification | Formes farmacèutiques | - |
dc.subject.classification | Malalties del còlon | - |
dc.subject.other | Antineoplastic agents | - |
dc.subject.other | Pharmaceutical dosage forms | - |
dc.subject.other | Colonic diseases | - |
dc.title | Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer; results of a phase I dose escalation trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 647931 | - |
dc.date.updated | 2020-01-29T15:29:51Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 22027708 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
647931.pdf | 357.03 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.